ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 135 entries already.
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.
Sanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired through the acquisition of Translate Bio in 2021.
AstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade ago.
Welsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging from stealth.
Spanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030 through its two specialist venture funds.
Swedish biotech PharmNovo has raised about SEK39m (€3.5m) to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain.
French biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leukaemia.
Roche has discontinued two Huntington’s disease programmes after its Ionis-partnered drug tominersen failed to improve patients’ symptoms and a separate candidate raised concerns in animal studies.
AstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), denting hopes that the RNA-targeted therapy could compete in one of cardiology’s fastest-growing rare disease markets.
GSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks.